Ketoconazole and Trenbolone Interaction: Monitor | Peptide Database

Join others researching Crystagen — share findings, ask questions, and learn from real experiences Crystagen is a Khavinson bioregulator tripeptide (EDP) identified in thymalin with selective action on thymus tissues. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it enhances immune function by stimulating normal lymphocyte proliferation while inhibiting tumor cell growth. Research shows effectiveness in normalizing immunity in 82% of elderly patients (vs 56% control) and reducing respiratory infections in athletes by doubling HSP gene expression. Crystagen works through epigenetic regulation by influencing gene expression and protein synthesis in immune cells. It regulates the synthesis of heat-shock proteins, cytokines, and affects cell differentiation, proliferation, and apoptosis. The EDP peptide enhances spontaneous proliferative activity of normal lymphocytes while inhibiting proliferation of tumor cells (K-562 erythromyelosis). It activates B-cell immune system and thymic epithelial cells (VTEC2.H/S).

Join others researching Telmisartan — share findings, ask questions, and learn from real experiences Telmisartan is an angiotensin II receptor blocker (ARB) originally developed for the treatment of hypertension and cardiovascular risk reduction. FDA-approved since 1998 and marketed as Micardis, it has become the preferred ARB among performance-enhancing drug users and anabolic steroid communities due to its long half-life, strong evidence for organ protection, and unique partial PPAR-gamma agonist activity. Unlike other ARBs, telmisartan activates peroxisome proliferator-activated receptor gamma (PPAR-gamma) at clinically relevant doses, conferring metabolic benefits that extend beyond blood pressure reduction. Anabolic androgenic steroids (AAS) are well-documented to elevate blood pressure, promote left ventricular hypertrophy, accelerate atherosclerosis, and impair renal function -- making proactive cardiovascular protection an essential component of harm reduction. Telmisartan addresses these concerns with once-daily dosing, 24-hour blood pressure coverage, and a favorable side effect profile that does not impair exercise performance or recovery. Telmisartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from exerting its vasoconstrictive, aldosterone-secreting, and pro-fibrotic effects. By antagonizing AT1, telmisartan lowers systemic vascular resistance and blood pressure while simultaneously reducing pathological cardiac and vascular remodeling. This is particularly relevant for AAS users, where supraphysiological androgen levels stimulate the renin-angiotensin-aldosterone system (RAAS) and promote myocardial fibrosis and left ventricular hypertrophy. Telmisartan also has the longest half-life of any ARB (approximately 24 hours), providing consistent receptor blockade throughout the dosing interval. Its unique partial agonism of PPAR-gamma -- a nuclear receptor involved in glucose and lipid metabolism -- distinguishes it from other ARBs. PPAR-gamma activation enhances insulin sensitivity, improves adiponectin secretion, reduces visceral fat accumulation, and exerts anti-inflammatory effects. Additionally, telmisartan demonstrates nephroprotective properties by reducing intraglomerular pressure and proteinuria, and has been shown in the ONTARGET trial to provide cardiovascular protection comparable to the ACE inhibitor ramipril in high-risk patients.